Articles related to ANTIBODY-DRUG CONJUGATES (ADC)

Phase 3 ASCENT-04 data presented at ASCO 2026 showed improved PFS2 for sacituzumab govitecan plus pembrolizumab over chemotherapy plus pembrolizumab in previously untreated PD-L1-positive advanced triple-negative breast cancer, though an independent expert challenged PFS2 as a valid endpoint for establishing frontline standard-of-care status.

Osimertinib plus datopotamab deruxtecan produced 20.5-month median duration of response at the 6 mg/kg dose in EGFR-mutated NSCLC after first-line osimertinib progression in the ORCHARD platform substudy.

The Trop-2-directed antibody-drug conjugate demonstrated a 2.3-month improvement in progression-free survival compared to standard chemotherapy options, offering a new treatment pathway for patients with limited options.

The DESTINY-Breast06 trial demonstrates the potential for earlier use of trastuzumab deruxtecan in HR+, HER2-low, and HER2-ultralow advanced or metastatic breast cancer, with significant improvements in progression-free survival compared to conventional chemotherapy.

MacroGenics’ Phase II TAMARACK trial for vobramitamab duocarmazine in metastatic prostate cancer reported five patient deaths, raising critical safety concerns but also highlighting promising response rates that could influence future treatment protocols.

Enhertu, now FDA approved for HER2-positive solid tumors, shows a notable objective response rate across pivotal trials, providing a significant new option for patients with advanced disease stages.